PROANGIOGENNYE FAKTORY V SYVOROTKE KROVI I OPUKhOLI BOL'NYKh RAKOM POChKI

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Folkman J. Antiangiogenesis: new concept for therapy of solid tumors // Ann. Surg.- 1972.- Vol. 175, № 3.- P. 409-416.
Ferrara N., Gerber H. P., LeCouter J. The biology of VEGF and its receptors // Nat. Med.- 2003.- Vol. 9, № 6.- P. 669-676.
Welsh S. J., Fife K. Pazopanib for the treatment of renal cell carcinoma // Future Oncol.- 2015.- Vol. 11, № 8.- P. 1169-1179.
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis / Iacovelli R., Sternberg C. N., Porta C., Verzoni E., de Braud F., Escudier B., Procopio G. // Curr. Drug Targets.- 2015.- Vol. 16, № 2.- P. 164-170.
Rini B. I., Small E. J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma // J. Clin. Oncol.- 2005.- Vol. 23, № 5.- P. 1028-1043.

Supplementary Files

Action

1. JATS XML